Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit
- PMID: 20188252
- PMCID: PMC2830913
- DOI: 10.1016/j.vaccine.2009.10.099
Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit
Abstract
We have previously reported that therapeutic immunization by intramuscular injection of optimized plasmid DNAs encoding SIV antigens effectively induces immune responses able to reduce viremia in antiretroviral therapy (ART)-treated SIVmac251-infected Indian rhesus macaques. We subjected such therapeutically immunized macaques to a second round of therapeutic vaccination using a combination of plasmids expressing SIV genes and the IL-15/IL-15 receptor alpha as molecular adjuvant, which were delivered by the more efficacious in vivo constant-current electroporation. A very strong induction of antigen-specific responses to Gag, Env, Nef, and Pol, during ART (1.2-1.6% of SIV-specific T cells in the circulating T lymphocytes) was obtained with the improved vaccination method. Immunological responses were characterized by the production of IFN-gamma, IL-2, and TNF-alpha either alone, or in combination as double or triple cytokine positive multifunctional T cells. A significant induction of CD4(+) T cell responses, mainly targeting Gag, Nef, and Pol, as well as of CD8(+) T cells, mainly targeting Env, was found in both T cells with central memory and effector memory markers. After release from ART, the animals showed a virological benefit with a further approximately 1 log reduction in viremia. Vaccination with plasmid DNAs has several advantages over other vaccine modalities, including the possibility for repeated administration, and was shown to induce potent, efficacious, and long-lasting recall immune responses. Therefore, these data support the concept of adding DNA vaccination to the HAART regimen to boost the HIV-specific immune responses.
Published by Elsevier Ltd.
Figures












Similar articles
-
Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses.J Immunol. 2002 Nov 1;169(9):4778-87. doi: 10.4049/jimmunol.169.9.4778. J Immunol. 2002. PMID: 12391187
-
Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques.J Immunol. 2008 Jun 15;180(12):7969-79. doi: 10.4049/jimmunol.180.12.7969. J Immunol. 2008. PMID: 18523260 Clinical Trial.
-
Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation.Vaccine. 2008 Sep 19;26(40):5223-9. doi: 10.1016/j.vaccine.2008.03.090. Epub 2008 Apr 21. Vaccine. 2008. PMID: 18468743 Free PMC article.
-
Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.Vaccine. 2006 Mar 10;24(11):1811-20. doi: 10.1016/j.vaccine.2005.10.026. Epub 2005 Oct 25. Vaccine. 2006. PMID: 16274888
-
Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating adenovirus-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge.J Virol. 2008 Nov;82(21):10911-21. doi: 10.1128/JVI.01129-08. Epub 2008 Aug 27. J Virol. 2008. PMID: 18753198 Free PMC article.
Cited by
-
Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection.Hum Vaccin Immunother. 2018 Jul 3;14(7):1820-1831. doi: 10.1080/21645515.2018.1448328. Epub 2018 Apr 12. Hum Vaccin Immunother. 2018. PMID: 29648490 Free PMC article.
-
Rapid transient and longer-lasting innate cytokine changes associated with adaptive immunity after repeated SARS-CoV-2 BNT162b2 mRNA vaccinations.Front Immunol. 2023 Nov 27;14:1292568. doi: 10.3389/fimmu.2023.1292568. eCollection 2023. Front Immunol. 2023. PMID: 38090597 Free PMC article.
-
Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques.Vaccine. 2011 Sep 9;29(39):6742-54. doi: 10.1016/j.vaccine.2010.12.056. Epub 2010 Dec 30. Vaccine. 2011. PMID: 21195080 Free PMC article.
-
Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?Retrovirology. 2012 Sep 7;9:72. doi: 10.1186/1742-4690-9-72. Retrovirology. 2012. PMID: 22958464 Free PMC article. Review.
-
Therapeutic Potential of IL-15 and N-803 in HIV/SIV Infection.Viruses. 2021 Sep 2;13(9):1750. doi: 10.3390/v13091750. Viruses. 2021. PMID: 34578331 Free PMC article. Review.
References
-
- Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol. 1998;16:867–870. - PubMed
-
- Andrieu JM, Lu W. A dendritic cell-based vaccine for treating HIV infection: background and preliminary results. J Intern Med. 2007;261:123–131. - PubMed
-
- Bansal A, Jackson B, West K, Wang S, Lu S, Kennedy JS, Goepfert PA. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J Virol. 2008;82:6458–6469. - PMC - PubMed
-
- Bergamaschi C, Rosati M, Jalah R, Valentin A, Kulkarni V, Alicea C, Zhang GM, Patel V, Felber BK, Pavlakis GN. Intracellular interaction of interleukin IL-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. J Biol Chem. 2007;283:4189–4199. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials